innovative drugs
Coverage of innovative drugs in the Nexus archive.
- China’s drug industry pivots to AI-powered candidates to drive next wave of deals
China's drug industry is shifting focus to AI-powered drug candidates to drive future deals, following record US$110 billion in cross-border transactions for innovative drugs in the first half of 2026. China accounts for 30% of globally developed new drugs, ranking second worldwide.
- China’s drug industry pivots to AI-powered candidates to drive next wave of deals
China's cross-border deals for innovative drugs reached $110 billion in H1 2026, with the industry now focusing on AI-powered candidates to drive future transactions. China holds 30% of globally developed new drugs, ranking second worldwide, according to Lan Gongtao from the National Medical Products Administration.
- China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom
China’s National Medical Products Administration (NMPA) approved 19 innovative drugs in 2024, with 15 developed by domestic companies, highlighting the country’s biotech growth. Notable approvals include sonrotoclax by BeOne for treating adult blood cancers, as the regulator streamlines its approval process.
- Science takes on the world’s most lethal malignancy
A study published in Nature on 27 May 2026 highlights that advancements in early detection, innovative drugs, and a deeper understanding of lung cancer are leading to better patient outcomes.